Clinical Evidence on Psilocybin and Its Representation in Media Reporting: A Systematic Review.
7 affiliations
- 1Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada.
- 2Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
- 3Research Institute of St Joseph's Hamilton, Hamilton, Ontario, Canada.
- 4Centre for Health Research and Innovations on Psychedelics, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
- 5School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.
- 6Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada.
- 7Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Abstract
Importance
Psilocybin has received increased attention as a potential therapeutic intervention, but it is unclear whether news media reporting reflects the strengths and limitations of the clinical trial evidence.Objective
To describe the annual counts of published clinical trials of therapeutic psilocybin and contemporaneous media articles and compare tone, efficacy, and safety messaging.Evidence review
This systematic review included English-language randomized and nonrandomized trials of psilocybin for clinical indications published from January 1, 2014, to October 10, 2024, and media articles describing its clinical use published from January 1, 2014, to April 22, 2025. Trials were found by searching Medline, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials (CENTRAL) and were characterized by design, indication, use of psychotherapy, and reporting of efficacy and safety. Media articles were found through the Factiva database and were characterized by audience, tone, indication, efficacy claim, and safety content. Data were extracted by 2 reviewers. Risk of bias for randomized clinical trials was assessed descriptively using the Cochrane Risk of Bias tool.Findings
Annual counts of both published clinical trials (n = 70) and media reports (n = 172) increased from 2018 onward. Depression was the most common clinical indication in trials (47 [67%]) and media articles (138 [80%]), while media articles frequently referenced posttraumatic stress disorder (PTSD) (74 [43%]) and anxiety (72 [42%]) as clinical indications despite absent and limited trial evidence, respectively, for these conditions. Overall, 49 trials (70%) reported benefit for the primary indication; 125 media articles (73%) made at least 1 positive efficacy claim, and 122 (71%) adopted a favorable tone. Trials typically described small sample sizes of less than 100 participants (65 trials [93%]) and methodologic limitations. Overall, 31 trials (44%) reported safety outcomes, with some (24 [34%]) documenting short-term adverse events, such as transient anxiety, nausea, or headache; long-term safety was rarely assessed (4 trials [6%]). Only 51 media articles (30%) mentioned safety; when harms were discussed, potential long-term psychological risks were sometimes noted (12 articles [7%]).Conclusions and relevance
In this systematic review of clinical trials and media articles, both reported positive effects of therapeutic psilocybin with similar frequency. Academic publications were more cautious and explicit about methodologic limitations, whereas media reports often presented benefits as established, extrapolated them to indications with little or no trial evidence, and provided less safety information. Clarifying these differences in emphasis may support more transparent public communication of indication-specific evidence and uncertainty as interest in psilocybin-assisted treatments grows.
Related
- Definitions and reporting of 'failure' after rotator cuff repair: A systematic review of level I and level II evidence and proposal for standardisation.
- Demographic Representation in Clinical Trials for Transthyretin-Associated Cardiac Amyloidosis: A Systematic Review
- Reporting and interpretation of respiratory metagenomic results in clinical practice: a systematic review and consensus guidelines from the UK NHS Respiratory Metagenomics Network
- Precision Evidence Bench: Assessing PICO alignment and faithful reporting in clinical AI
- Hypoxic exposure and air-quality reporting in normobaric hypoxic resistance training: a systematic evidence map and exploratory meta-analysis
BibTeX
@article{madden2026clinical,
title = {{Clinical Evidence on Psilocybin and Its Representation in Media Reporting: A Systematic Review.}},
author = {Kim Madden and Breanne Flood and Imad Kashir and Rayan Ahmad and Hiba Ali and Rotem Petranker and James MacKillop and Anthony Adili},
journal = {JAMA network open},
year = {2026},
month = oct,
doi = {10.1001/jamanetworkopen.2026.38843},
url = {https://europepmc.org/article/MED/42900476},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Clinical Evidence on Psilocybin and Its Representation in Media Reporting: A Systematic Review.
AU - Kim Madden
AU - Breanne Flood
AU - Imad Kashir
AU - Rayan Ahmad
AU - Hiba Ali
AU - Rotem Petranker
AU - James MacKillop
AU - Anthony Adili
PY - 2026
DA - 2026/10/01
JO - JAMA network open
DO - 10.1001/jamanetworkopen.2026.38843
UR - https://europepmc.org/article/MED/42900476
AB - Importance Psilocybin has received increased attention as a potential therapeutic intervention, but it is unclear whether news media reporting reflects the strengths and limitations of the clinical trial evidence.Objective To describe the annual counts of published clinical trials of therapeutic psilocybin and contemporaneous media articles and compare tone, efficacy, and safety messaging.Evidence review This systematic review included English-language randomized and nonrandomized trials of psilocybin for clinical indications published from January 1, 2014, to October 10, 2024, and media articles describing its clinical use published from January 1, 2014, to April 22, 2025. Trials were found by searching Medline, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials (CENTRAL) and were characterized by design, indication, use of psychotherapy, and reporting of efficacy and safety. Media articles were found through the Factiva database and were characterized by audience, tone, indication, efficacy claim, and safety content. Data were extracted by 2 reviewers. Risk of bias for randomized clinical trials was assessed descriptively using the Cochrane Risk of Bias tool.Findings Annual counts of both published clinical trials (n = 70) and media reports (n = 172) increased from 2018 onward. Depression was the most common clinical indication in trials (47 [67%]) and media articles (138 [80%]), while media articles frequently referenced posttraumatic stress disorder (PTSD) (74 [43%]) and anxiety (72 [42%]) as clinical indications despite absent and limited trial evidence, respectively, for these conditions. Overall, 49 trials (70%) reported benefit for the primary indication; 125 media articles (73%) made at least 1 positive efficacy claim, and 122 (71%) adopted a favorable tone. Trials typically described small sample sizes of less than 100 participants (65 trials [93%]) and methodologic limitations. Overall, 31 trials (44%) reported safety outcomes, with some (24 [34%]) documenting short-term adverse events, such as transient anxiety, nausea, or headache; long-term safety was rarely assessed (4 trials [6%]). Only 51 media articles (30%) mentioned safety; when harms were discussed, potential long-term psychological risks were sometimes noted (12 articles [7%]).Conclusions and relevance In this systematic review of clinical trials and media articles, both reported positive effects of therapeutic psilocybin with similar frequency. Academic publications were more cautious and explicit about methodologic limitations, whereas media reports often presented benefits as established, extrapolated them to indications with little or no trial evidence, and provided less safety information. Clarifying these differences in emphasis may support more transparent public communication of indication-specific evidence and uncertainty as interest in psilocybin-assisted treatments grows.
SN - 2574-3805
ER -